c-peptide levels predict the effectiveness of dipeptidyl peptidase-4 inhibitor therapy
Clicks: 251
ID: 142188
2016
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Steady Performance
30.0
/100
251 views
23 readers
AI Quality Assessment
Not analyzed
Readership in this journal
SteadyRanked #30 of 157 articles by views in applied computer science
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 157 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Background. Our aim was to define the conditions that affect therapeutic success when dipeptidyl peptidase-4 (DPP-4) inhibitor is added to metformin monotherapy. Materials and Methods. We reviewed the medical records of 56 patients who had received DPP-4 inhibitor as an add-on to metformin monotherapy and evaluated their response in the first year of therapy. Fasting blood glucose (FBG), HbA1c, C-peptide, and weight of the patients were recorded at 3-month intervals during the first year of treatment. Results. Patients who added DPP-4 inhibitor to metformin monotherapy had significant weight loss (P=0.004) and FBG and HbA1c levels were significantly lowered during the first 6 months (both P<0.001). Baseline levels of C-peptide were predictive for success of the treatment (P=0.02), even after correction for confounding factors, for example, age, gender, or BMI (P=0.03). Duration of diabetes was not a predictor of response to treatment (P=0.60). Conclusion. Our study demonstrates that in patients having inadequate glycemic control, the addition of a DPP-4 inhibitor as a second oral agent to metformin monotherapy provides better glycemic control, protects β-cell reserves, and does not cause weight gain. These effects depend on baseline C-peptide levels.
Abstract Quality Issue:
This abstract appears to be incomplete or contains metadata (105 words).
Try re-searching for a better abstract.
| Reference Key |
demir2016journalc-peptide
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | ;Sevin Demir;Sule Temizkan;Mehmet Sargin |
| Journal | applied computer science |
| Year | 2016 |
| DOI |
10.1155/2016/4509603
|
| URL | |
| Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.